CIENCIASMEDICASNEWS: 2025

viernes, 26 de diciembre de 2025

New CMS models could reshape the landscape for lifestyle medicine practice and reimbursement ++++ ++++

New CMS models could reshape the landscape for lifestyle medicine practice and reimbursement https://www.news-medical.net/news/20251212/New-CMS-models-could-reshape-the-landscape-for-lifestyle-medicine-practice-and-reimbursement.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 The American College of Lifestyle Medicine (ACLM) applauds two new Centers for Medicare and Medicaid Services (CMS) models that could significantly reshape the landscape for lifestyle medicine practice and reimbursement. Plant-based diets support healthy growth when properly planned for children https://www.news-medical.net/news/20251212/Plant-based-diets-support-healthy-growth-when-properly-planned-for-children.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Plant-based diets support healthy growth when properly planned for childrenVegetarian and vegan diets can support healthy growth when carefully planned with appropriate supplementation, finds a major new meta-analysis – the most comprehensive study to-date of plant-based diets in children. Lowering blood sugar reduces heart risk in prediabetes https://www.news-medical.net/news/20251212/Lowering-blood-sugar-reduces-heart-risk-in-prediabetes.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Lowering blood sugar levels halves the likelihood of serious heart problems in people with prediabetes. Frequency and quantity of alcohol consumption influence cancer risk https://www.news-medical.net/news/20251211/Frequency-and-quantity-of-alcohol-consumption-influence-cancer-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the long-term health effects of raising a celebratory glass – or two. New research reveals underestimation of food insecurity https://www.news-medical.net/news/20251213/New-research-reveals-underestimation-of-food-insecurity.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 New research reveals underestimation of food insecurityBefore you can address a problem, you need to understand its scope. That's why the United Nations developed the Integrated Food Security Phase Classification System. Aid organizations rely on analyses from this global partnership, which monitors and classifies the severity of food insecurity to help target assistance where and when it is most needed. How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS https://www.news-medical.net/news/20251216/How-Traditional-Chinese-Medicine-may-reshape-the-gut-microbiome-to-ease-insulin-resistance-in-PCOS.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOSThis review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization. Many parents struggle to navigate conversations about nutrition with teens https://www.news-medical.net/news/20251215/Many-parents-struggle-to-navigate-conversations-about-nutrition-with-teens.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 As teens gain more independence in their food choices, many parents struggle to navigate conversations about nutrition -which could be especially important during the holidays, when celebrations often center around meals. Indiana University physician joins FDA panel on male hormone therapy https://www.news-medical.net/news/20251212/Indiana-University-physician-joins-FDA-panel-on-male-hormone-therapy.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Indiana University physician joins FDA panel on male hormone therapyHelen Bernie, DO, MPH, assistant professor of urology at Indiana University School of Medicine, will participate in an expert panel on testosterone replacement therapy and men's health to be held Wednesday, Dec. 10, by the U.S. Food and Drug Administration. Bernie's role on the panel is that of a clinical expert on men's reproductive health, which is the focus of both her practice and academic research.

High fructose intake increases fatty liver risk ++++ +++

High fructose intake increases fatty liver risk https://www.news-medical.net/news/20251216/High-fructose-intake-increases-fatty-liver-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 High fructose intake increases fatty liver riskExcessive fructose intake from soft drinks is linked to liver damage and NAFLD. Lifestyle modifications are essential for effective prevention and treatment. Unnecessary gluten-free diets may put children at risk https://www.news-medical.net/news/20251215/Unnecessary-gluten-free-diets-may-put-children-at-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Unnecessary gluten-free diets may put children at riskUnderstanding gluten-related disorders is crucial for pediatric nutrition, as gluten-free diets can pose health risks without appropriate medical supervision. A new trial investigates whether the MIND diet can be scaled for obesity management https://www.news-medical.net/news/20251214/A-new-trial-investigates-whether-the-MIND-diet-can-be-scaled-for-obesity-management.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 A new trial investigates whether the MIND diet can be scaled for obesity managementThis study protocol outlines a 12-week randomized trial testing whether a MIND diet intervention is feasible, acceptable, and sustainable for adults with obesity in Sweden. It will generate preliminary evidence on adherence, mental well-being, and gut microbiota changes to inform larger efficacy trials. Scientists map how cinnamon’s bioactives interact with cancer signaling https://www.news-medical.net/news/20251215/Scientists-map-how-cinnamone28099s-bioactives-interact-with-cancer-signaling.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Scientists map how cinnamon’s bioactives interact with cancer signalingThis review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative stress, apoptosis, and angiogenesis through multiple cancer-related signaling pathways. While biologically plausible, the findings are largely limited to cell and animal models, underscoring the need for pharmacokinetic, safety, and clinical validation. Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk https://www.news-medical.net/news/20251214/Swapping-high-carb-snacks-for-tree-nuts-cuts-food-cravings-in-young-adults-at-metabolic-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic riskDaily replacement of typical high-carbohydrate snacks with mixed tree nuts for 16 weeks reduced cravings for sweets and fast foods in young adults with early metabolic syndrome risk. This dietary swap improved overall diet quality, measured by the Healthy Eating Index, without increasing body weight or altering short-term glycaemic markers. How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really help https://www.news-medical.net/news/20251211/How-ultra-processed-foods-shape-Crohne28099s-disease-risk-and-what-dietary-strategies-can-really-help.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really helpThis narrative review synthesizes evidence showing that higher intake of ultra-processed foods is consistently associated with increased Crohn’s disease risk, with mechanistic pathways implicating emulsifiers, carrageenan, maltodextrin, titanium dioxide, sweeteners and salt. It also highlights that minimally processed dietary strategies, including EEN and CDED, show therapeutic promise, particularly in pediatric Crohn’s disease. What happens to your body during an ultramarathon? New study reveals key metabolic changes https://www.news-medical.net/news/20251210/What-happens-to-your-body-during-an-ultramarathon-New-study-reveals-key-metabolic-changes.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 What happens to your body during an ultramarathon? New study reveals key metabolic changesThis study tracked ultramarathon runners across 100 km, 160.9 km, and 230 km events to examine real-world metabolic, hormonal, and muscle stress responses. Severe energy deficits, muscle damage, and heterogeneous hormonal shifts were observed, with the greatest strain seen in the 230 km distance.

What happens to your body when you eat takeaway food too often? +++++

https://www.news-medical.net/news/20251211/What-happens-to-your-body-when-you-eat-takeaway-food-too-often.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 New evidence reveals how frequent takeaway meals elevate dietary inflammation and quietly reshape key metabolic risk factors, underscoring why reducing high-frequency takeaway habits could meaningfully improve long-term heart and metabolic health. What drinking kefir really does to your gut and oral microbiome A comprehensive review of human studies reveals that kefir can alter certain gut and oral bacteria. However, inconsistent results and small trials mean its true health impact remains an open scientific question. https://www.news-medical.net/news/20251215/What-drinking-kefir-really-does-to-your-gut-and-oral-microbiome.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 How much omega-3 do you need daily? New global review reveals DHA and EPA requirements https://www.news-medical.net/news/20251210/How-much-omega-3-do-you-need-daily-New-global-review-reveals-DHA-and-EPA-requirements.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Global and national guidelines for long-chain omega-3 intake vary widely across life stages, with many countries lacking clear recommendations. Most authorities advise at least 250 mg/day of EPA and DHA, yet population intakes remain far below optimal levels. How specific foods reshape oxidative stress responses during and after high-intensity trainingHow specific foods reshape oxidative stress responses during and after high-intensity training https://www.news-medical.net/news/20251211/How-specific-foods-reshape-oxidative-stress-responses-during-and-after-high-intensity-training.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 Carbohydrate-rich foods blunt acute oxidative stress during fasted high-intensity exercise, while polyphenol-rich foods accelerate early recovery by reducing post-exercise ROS. Findings highlight how nutrient timing shapes redox responses in sedentary young women undergoing resistance-circuit HIIT. White bread vs wholegrain: which one is actually better for your health?White bread vs wholegrain: which one is actually better for your health? https://www.news-medical.net/news/20251211/White-bread-vs-wholegrain-which-one-is-actually-better-for-your-health.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025 This review dispels common myths about white and wholegrain bread by examining their composition processing and health effects. It concludes that while wholegrain breads offer added benefits white bread remains a safe affordable and nutritionally meaningful staple when fortified.

Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients. Maram Alshreef, Hanin AbaAlkhayl, Qoot Almdainy, Abdulaziz Alshammari, Shahad Alajmi, Shatha Alruwaite, Ebtisam Alqahtani, Reema Almalke, Tagreed Alonazi International Journal of Clinical Pharmacology and Therapeutics 2025 December 5

https://read.qxmd.com/read/41347381/comparison-of-vasopressin-first-weaning-versus-norepinephrine-first-weaning-in-critically-ill-patients?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients. Septic shock is a critical condition requiring vasopressor support and mechanical ventilation. The sequence of vasopressor weaning may affect clinical outcomes,.. Dec 5, 2025: International Journal of Clinical Pharmacology and Therapeutics

Rab23 GTPase and IFT43 regulate the trafficking of prostaglandin E receptor 4 to primary cilia. Yewei Chen, Yating Zhou, Yao Qi, Tingting Miao, Jianan Shi, Daqing Jin, Tao P Zhong Communications Biology 2025 December 10

https://read.qxmd.com/read/41372612/rab23-gtpase-and-ift43-regulate-the-trafficking-of-prostaglandin-e-receptor-4-to-primary-cilia?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Rab23 GTPase and IFT43 regulate the trafficking of prostaglandin E receptor 4 to primary cilia. Primary cilia are crucial organelles involved in various cellular signaling pathways. Prostaglandin E receptor 4 (EP4), a G protein-coupled receptor (GPCR), loc.. Dec 10, 2025: Communications Biology

What is the impact of nutrition interventions on incidence of anastomotic leak after colorectal surgery? A systematic review of randomized trials. Leslee Hasil, Andrew Milks, Angelea Panagakos, Dominique Engel, Emily Jaeger-McEnroe, Chelsia Gillis European Journal of Surgical Oncology 2025 December 4

https://read.qxmd.com/read/41401601/what-is-the-impact-of-nutrition-interventions-on-incidence-of-anastomotic-leak-after-colorectal-surgery-a-systematic-review-of-randomized-trials?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug What is the impact of nutrition interventions on incidence of anastomotic leak after colorectal surgery? A systematic review of randomized trials. Nutrition-related factors have been associated with increased incidence of anastomotic leak (AL) following colorectal surgery; however, specific perioperative n.. Dec 4, 2025: European Journal of Surgical Oncology

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Vanja Zeremski, Enver Aydilek, Akhil Behringer, Franziska Brunner, Tobias Ronny Haage, Mathias Haenel, Igor Age Kos, William Hermann Krueger, Georg Lenz, Vadim Lesan, Jessica Schneider, Christian R Schultze-Florey, Evgenii Shumilov, Thomas Weber, Gerald Georg Wulf, Vladan Vucinic, Dimitrios Mougiakakos Blood Advances 2025 December 18

https://read.qxmd.com/read/41411524/early-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma-is-associated-with-lower-hematotoxicity-burden?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Dec 18, 2025: Blood Advances

HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. Seohyuk Lee, Adriana M Kahn, Mariya Rozenblit, Mridula A George, Cristina Naranjo Ortiz, Maryam B Lustberg Cancer Medicine 2025 December

https://read.qxmd.com/read/41361931/her2-targeted-antibody-drug-conjugate-toxicities-in-breast-cancer?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. HER2-targeted antibody-drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2-targeted ADCs, trastuzumab deruxtecan and trastuzumab .. Dec 2025: Cancer Medicine

An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. Wei-Zhen Bai, Shi-Yu Zhou, Yuan-Yuan Mou, Liao Peng, Ling-Li Li Medicine (Baltimore) 2025 December 5

https://read.qxmd.com/read/41366890/an-updated-meta-analysis-of-head-to-head-trials-comparing-the-efficacy-safety-and-adherence-of-mirabegron-and-vibegron-in-overactive-bladder?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. This updated meta-analysis aimed to compare the efficacy, safety, and treatment adherence of mirabegron and vibegron in patients with overactive bladder with he.. Dec 5, 2025: Medicine (Baltimore)

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial. Everett Meyer, Amandeep Salhotra, Arpita Gandhi, Jeremy Pantin, Sagar S Patel, Rasmus T Hoeg, Alexandra Gomez-Arteaga, Rawan G Faramand, Roni Tamari, Edmund K Waller, Satyajit Kosuri, Antonio M Jimenez Jimenez, Jennifer Holter-Chakrabarty, Bhagirathbhai Dholaria, Yi-Bin Chen, Betty K Hamilton, John M Magenau, Alireza Eghtedar, Joshua M Murray, Anna Pavlova, Nathaniel B Fernhoff, James Scott McClellan, Scott Killian, Ai Li, Robert S Negrin, Caspian Oliai

https://read.qxmd.com/read/41385341/orca-t-versus-allogeneic-hematopoietic-stem-cell-transplantation-precision-t-a-multicenter-randomized-phase-3-trial?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial. To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin in.. Dec 12, 2025: Blood

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. A De Giglio, L Zullo, A Di Federico, M Cani, M Aldea, D Soldato, F G Dall'Olio, F Mantuano, F Sperandi, V Favorito, A Sadowska, L E L Hendriks, T Gorria, L Mezquita, F Tabbò, S Novello, F Gelsomino, B Besse, A Ardizzoni

https://read.qxmd.com/read/41252810/immunotherapy-beyond-progression-combined-with-platinum-based-chemotherapy-after-primary-resistance-to-first-line-immunotherapy-in-patients-with-advanced-nsclc-and-pd-l1-50?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. Primary resistance to immune checkpoint inhibitors (ICIs) remains a major challenge in patients with advanced non-small-cell lung cancer (NSCLC) and programmed .. Nov 17, 2025: ESMO Open

Ultrasound indicators of organ venous congestion: a narrative review. Zouheir Ibrahim Bitar, Ossama Sajeh Maadarani, Mohamad Bitar

https://read.qxmd.com/read/41251929/ultrasound-indicators-of-organ-venous-congestion-a-narrative-review?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Ultrasound indicators of organ venous congestion: a narrative review. Acute kidney injury and other organ dysfunction in the setting of heart failure are primarily determined by a low cardiac output status and venous congestion, w.. Nov 18, 2025: Annals of Intensive Care

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Alberto Martínez-Castelao, José Luis Górriz, Beatriz Fernández-Fernández, María José Soler, Juan F Navarro-González

https://read.qxmd.com/read/41375628/diabetes-mellitus-and-chronic-kidney-disease-the-future-is-being-surpassed?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health is.. Nov 23, 2025: Journal of Clinical Medicine

Foreign Bodies in the Head, Neck, Airways, and Extremities: Curious Findings Christopher E. Roberts, MD; Paul M. Bunch, MD, MS December 15, 2025

https://reference.medscape.com/p11/foreign-bodies-head-neck-airways-and-extremities-ss-2025a1000ybl?ecd=wnl_critimg_251226_mscpref_etid7976547&uac=148436CN&impID=7976547

Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP

Comunicación para mejorar la atención a través de los datos y la experiencia del paciente: Edición de cáncer de mama metastásico ER positivo/HER2 negativo Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP https://www.medscape.org/viewarticle/communicating-enhance-care-through-data-and-patient-2025a1000uqi?page=1

UK Prostate MRI Practice Shows Progress; Variations Persist Edited by Mamta Pawara Medscape UK December 26, 2025

https://www.medscape.com/viewarticle/uk-prostate-mri-practice-shows-progress-variations-persist-2025a1001091

Immunotherapy in Early-Stage Cancers: Multidisciplinary Team Best Practices Authors: Nadia Harbeck, MD, PhD; Enriqueta Felip, MD; Elizabeth Mittendorf, MD; Suresh Senan, MD

https://www.medscape.org/viewarticle/1002762?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251225-OUS-HONC-1002762-cta

Optimizing Outcomes With Radiopharmaceuticals in mCRPC Care: From Evidence to Execution Authors: Joe O’Sullivan, PhD, MD, BAO, BCH, FRCR, FFRRCSI, FRCPI; Irene Burger, MD; Elena Castro, MD, PhD; Bertrand Tombal, MD, PhD

https://www.medscape.org/viewarticle/1003032?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251225-OUS-HONC-1003032-cta

Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD

https://www.medscape.org/viewarticle/1002660?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251225-OUS-HONC-1002660-cta

Navigating the Storm of Heavily Pretreated Multiple Myeloma: Calming the Waters With Bispecific Antibodies Authors: Hermann C. Einsele, MD, PhD; Xavier Leleu, MD, PhD; Naresh Bumma, MD

https://www.medscape.org/viewarticle/1002692?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251226-OUS-HONC-1002692-cta

jueves, 25 de diciembre de 2025

Discovery of a fat-regulating enzyme points to a new obesity therapy

https://www.news-medical.net/news/20251223/Discovery-of-a-fat-regulating-enzyme-points-to-a-new-obesity-therapy.aspx

Alcohol consumption plays a major role in India’s mouth cancer burden

https://www.news-medical.net/news/20251223/Alcohol-consumption-plays-a-major-role-in-Indiae28099s-mouth-cancer-burden.aspx

Navigating Biomarker Conversations: Empowering Patient Understanding in Gastroesophageal Cancer Authors: Sylvie Lorenzen, MD, PhD

https://www.medscape.org/viewarticle/1002840?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1002840-cta

Antibody-Drug Conjugates in Practice: Contemporary Questions for the Treatment of Metastatic Breast Cancer Authors: Judy King, MRCP, PhD; Giuseppe Curigliano, MD, PhD; Peter Schmid, MD, PhD, FRCP

https://www.medscape.org/viewarticle/1002851?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251223-OUS-HONC-1002851-cta

Routine PSA Screening May Do More Harm Than Good ++++++

News & Perspectives: Fast Five Quiz: Presentation and Diagnosis of Iron-Deficiency Anemia Fast Five Quiz: Presentation and Diagnosis of Iron-Deficiency Anemia Reviewed by Ruben Rhoades, MD, MS https://reference.medscape.com/viewarticle/anemia-presentation-and-diagnosis-2025a1000u76?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 The Year’s 10 Best Gastroenterology Guidelines The Year’s 10 Best Gastroenterology Guidelines David A. Johnson, MD https://www.medscape.com/viewarticle/years-10-best-gastroenterology-guidelines-2025a1000zqj?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 December 23, 2025 Hope for Huntington’s With Possible Breakthrough Gene Therapy Hope for Huntington’s With Possible Breakthrough Gene Therapy Andrew N. Wilner, MD; Victor Sung, MD https://www.medscape.com/viewarticle/hope-huntingtons-possible-breakthrough-gene-therapy-2025a1000zqb?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 December 23, 2025 Hereditary Angioedema: 5 Things to Know Hereditary Angioedema: 5 Things to Know Jonathan A. Bernstein, MD https://www.medscape.com/viewarticle/hereditary-angioedema-5-things-know-2025a1000t8t?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 December 23, 2025 ESMO: Pembrolizumab Neoadjuvant/Adjuvant Outperforms Adjuvant Alone in Stage III Melanoma ESMO: Pembrolizumab Neoadjuvant/Adjuvant Outperforms Adjuvant Alone in Stage III Melanoma Teresa Amaral, MD, PhD https://www.medscape.com/viewarticle/esmo-pembrolizumab-neoadjuvant-adjuvant-outperforms-adjuvant-2025a1000yk1?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 December 23, 2025 Routine PSA Screening May Do More Harm Than Good Routine PSA Screening May Do More Harm Than Good Kenneth W. Lin, MD, MPH https://www.medscape.com/viewarticle/routine-psa-screening-may-do-more-harm-than-good-2025a1000zqw?ecd=wnl_edit_tpal_etid7984532&uac=148436CN&impID=7984532 December 23, 2025

Sugar Overload Killing Hearts By Ivanhoe Broadcast News on November 4, 2025

https://www.ivanhoe.com/family-health/sugar-overload-killing-hearts/

Emmitt’s Story: From A Head Cold to A Rare Heart Condition – In-Depth Doctor’s Interview By Ivanhoe Broadcast News on July 15, 2024

https://www.ivanhoe.com/interview/emmitts-story-from-a-head-cold-to-a-rare-heart-condition-in-depth-doctors-interview/

Wishful Thinking: Hoping For The Future By Ivanhoe Broadcast News on December 26, 2025

https://www.ivanhoe.com/?p=36461&preview=1&_ppp=91ce958498

Travel Luxe For Less By Ivanhoe Broadcast News on December 25, 2025

https://www.ivanhoe.com/smart-living/travel-luxe-for-less/

Work Without Feeling: Running On Empty By Ivanhoe Broadcast News on December 24, 2025

https://www.ivanhoe.com/smart-living/work-without-feeling-running-on-empty/

Priced Out Of Friendship: Finances & FOMO By Ivanhoe Broadcast News on December 23, 2025

https://www.ivanhoe.com/smart-living/priced-out-of-friendship-finances-fomo/

Toxic Taste: When Dinner Turns Dangerous By Ivanhoe Broadcast News on December 22, 2025

https://www.ivanhoe.com/smart-living/toxic-taste-when-dinner-turns-dangerous/

Personalized Progress in Advanced Ovarian Cancer: Integrating Biomarkers In First-Line Care Authors: Ritu Salani, MD, MBA; Jessica Walchonski, PA-C; Belinda Paulicin, DSW, LCSW, OWS-C

https://www.medscape.org/viewarticle/personalized-progress-advanced-ovarian-cancer-integrating-2025a1000zgz?page=1

Highlights in Hematologic Malignancies From the 2025 Winter Meeting Authors: Amer Zeidan, MBBS, MHS; John Mascarenhas, MD; Loretta Nastoupil, MD

https://www.medscape.org/viewarticle/highlights-hematologic-malignancies-2025-winter-meeting-2025a100100h?page=1

Medscape Now! Joubert Syndrome: Essential Knowledge for Healthcare Teams Authors: Blessing Ajayi, PA-C

https://www.medscape.org/viewarticle/medscape-now-joubert-syndrome-essential-knowledge-healthcare-2025a1000zv2?page=1

Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management Authors: Christopher R. D'Angelo, MD; Ayushi Chauhan, MD; Ashley L. Sumrall, MD, FACP, FASCO

https://www.medscape.org/viewarticle/targeted-therapies-rr-pcnsl-treatment-and-management-2025a1000zoj

Key Perspective: Enhancing Awareness, Diagnosis, and Management of Epithelioid Sarcoma

https://www.medscape.org/viewarticle/key-perspective-enhancing-awareness-diagnosis-and-management-2025a100101g

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow Authors: Yong Fang, MD; Hye Ryun Kim, MD, PhD; Hibiki Udagawa, MD, PhD

https://www.medscape.org/viewarticle/precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251224-OUS-HONC-1002681-cta

Building Consensus in Nonmelanoma Skin Cancer Care: Applying Emerging Science and Best Practices Authors: Axel Hauschild, MD; David M. Miller, MD, PhD; Vishal Anil Patel, MD; Marlies Wakkee, MD, PhD

https://www.medscape.org/viewarticle/building-consensus-nonmelanoma-skin-cancer-care-applying-2025a1000upd?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251224-OUS-HONC-building-consensus-nonmelanoma-skin-cancer-care-applying-2025a1000upd-cta

miércoles, 24 de diciembre de 2025

How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really help ++++++

Fear strongly influences pain perception in inflammatory bowel disease patients https://www.news-medical.net/news/20251212/Fear-strongly-influences-pain-perception-in-inflammatory-bowel-disease-patients.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Fear strongly influences pain perception in inflammatory bowel disease patientsPain perception in affected individuals is more strongly influenced by learned fear than in healthy individuals. Changes along the gut-brain axis related to chronic inflammation may explain this. Advances in delivering oxygen-sensitive gut bacteria improve microbial therapies https://www.news-medical.net/news/20251215/Advances-in-delivering-oxygen-sensitive-gut-bacteria-improve-microbial-therapies.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Advances in delivering oxygen-sensitive gut bacteria improve microbial therapiesRecent research has identified practical ways to protect and deliver oxygen-sensitive gut bacteria for a path toward safer, standardized microbial therapies that could reduce reliance on donor-based faecal microbiota transplants. White bread vs wholegrain: which one is actually better for your health? https://www.news-medical.net/news/20251215/Advances-in-delivering-oxygen-sensitive-gut-bacteria-improve-microbial-therapies.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 White bread vs wholegrain: which one is actually better for your health?This review dispels common myths about white and wholegrain bread by examining their composition processing and health effects. It concludes that while wholegrain breads offer added benefits white bread remains a safe affordable and nutritionally meaningful staple when fortified. How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really help https://www.news-medical.net/news/20251211/How-ultra-processed-foods-shape-Crohne28099s-disease-risk-and-what-dietary-strategies-can-really-help.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really helpThis narrative review synthesizes evidence showing that higher intake of ultra-processed foods is consistently associated with increased Crohn’s disease risk, with mechanistic pathways implicating emulsifiers, carrageenan, maltodextrin, titanium dioxide, sweeteners and salt. It also highlights that minimally processed dietary strategies, including EEN and CDED, show therapeutic promise, particularly in pediatric Crohn’s disease. Revolutionary quantum sensors could enable earlier cancer diagnosis and treatment https://www.news-medical.net/news/20251216/Revolutionary-quantum-sensors-could-enable-earlier-cancer-diagnosis-and-treatment.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 A revolutionary quantum sensing project that could transform cancer treatment by tracking how immune cells interact with tumors has been awarded a prestigious £2 million Future Leaders Fellowship. New CDC grant supports expansion of colorectal cancer screening across rural Pennsylvania https://www.news-medical.net/news/20251211/New-CDC-grant-supports-expansion-of-colorectal-cancer-screening-across-rural-Pennsylvania.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Increasing colorectal cancer screening rates among communities with the greatest need is the goal of a five-year, $4.2 million grant from the Centers for Disease Control and Prevention (CDC) to Penn State College of Medicine.

Scientists map how cinnamon’s bioactives interact with cancer signaling +++++

https://www.news-medical.net/news/20251215/Scientists-map-how-cinnamone28099s-bioactives-interact-with-cancer-signaling.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Laboratory studies suggest cinnamon’s bioactive compounds can alter key cancer-related signaling pathways, but researchers caution that human trials are essential before any preventive or therapeutic claims can be made. New insights explain the Treg paradox in colorectal cancer https://www.news-medical.net/news/20251215/New-insights-explain-the-Treg-paradox-in-colorectal-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Blood test identifies colon cancer patients who benefit from anti-inflammatory medicationBlood test identifies colon cancer patients who benefit from anti-inflammatory medication https://www.news-medical.net/news/20251215/Blood-test-identifies-colon-cancer-patients-who-benefit-from-anti-inflammatory-medication.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology. Frog-derived bacteria offer dual-action anticancer effects and high safetyFrog-derived bacteria offer dual-action anticancer effects and high safety https://www.news-medical.net/news/20251216/Frog-derived-bacteria-offer-dual-action-anticancer-effects-and-high-safety.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 A research team of Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) has discovered that the bacterium Ewingella americana, isolated from the intestines of Japanese tree frogs (Dryophytes japonicus), possesses remarkably potent anticancer activity. This groundbreaking research has been published in the international journal Gut Microbes. Early scans reveal prostate radiotherapy toxicity riskEarly scans reveal prostate radiotherapy toxicity risk https://www.news-medical.net/news/20251211/Early-scans-reveal-prostate-radiotherapy-toxicity-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_18_december_2025 Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests.

High-fat cheese and cream consumption links to lower dementia risk over 25 years

https://www.news-medical.net/news/20251223/High-fat-cheese-and-cream-consumption-links-to-lower-dementia-risk-over-25-years.aspx A long-running Swedish study suggests that not all dairy is equal for brain health, with high-fat cheese and cream showing unexpected associations with lower dementia risk.

Study Maps Genes Tied to Targets in IBS ++++++ +...

Study Maps Genes Tied to Targets in Irritable Bowel Syndrome Nathalie Raffier https://www.medscape.com/viewarticle/study-maps-genes-tied-targets-irritable-bowel-syndrome-2025a1000xzx?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 Medscape Europe December 04, 2025 Chronic Gut Pain’s Elusive Cause Found — and Possibly Fixed David Brzostowicki https://www.medscape.com/viewarticle/chronic-gut-pains-elusive-cause-found-and-possibly-fixed-2025a1000w33?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 November 18, 2025 Should You Prescribe a Low FODMAP Diet for IBS? Check for Eating Disorders First Nancy A. Melville https://www.medscape.com/viewarticle/should-you-prescribe-low-fodmap-diet-ibs-check-eating-2025a1000xnt?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 December 02, 2025 Study Sheds More Light on Long-Term Isotretinoin and Inflammatory Bowel Disease Risk Edited by Deepa Varma https://www.medscape.com/viewarticle/study-sheds-more-light-long-term-isotretinoin-and-2025a1000y8p?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 December 08, 2025 1 in 3 Worldwide Have Functional Bowel Disorders Edited by Archita Rai https://www.medscape.com/viewarticle/one-three-worldwide-have-functional-bowel-disorders-2025a1000sv2?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 October 23, 2025 The Impact of Emulsifiers on GI Health Batya Swift Yasgur, MA, LSW https://www.medscape.com/viewarticle/impact-emulsifiers-gi-health-2025a1000yl7?ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906 December 10, 2025 Compare the efficacy and safety profiles of linaclotide versus plecanatide for chronic idiopathic constipation (Medscape AI) https://www.medscape.com/ai-search?query=Compare%20the%20efficacy%20and%20safety%20profiles%20of%20linaclotide%20versus%20plecanatide%20for%20chronic%20idiopathic%20constipation&&ecd=mkm_ret_251223_mscpmrk-OUS_InFocus_etid7962906&uac=148436CN&impID=7962906

Why should docs avoid ordering broad food allergy panels for triggers (Medscape AI) +... ++++ ++++ ++ ++

Getting a Grip on Gastroparesis Understanding Slowed Digestion +++++

https://newsinhealth.nih.gov/2025/12/getting-grip-gastroparesis Probiotics https://ods.od.nih.gov/factsheets/Probiotics-Consumer/ Urinary Tract Health https://www.nichd.nih.gov/health/topics/urinary Health coaching before surgery may improve outcomes https://www.nih.gov/news-events/nih-research-matters/health-coaching-before-surgery-may-improve-outcomes The Truth About Holiday Spirits https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/truth-about-holiday-spirits

FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219083s000lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition Action The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Disease or Condition Symptomatic oHCM is an inherited condition where patients have thickened heart muscle and reduced blood flow from the left side of the heart to the rest of the body, causing symptoms such as shortness of breath, fatigue, and potentially life-threatening cardiac events. Myqorzo Effectiveness The effectiveness and safety of Myqorzo were studied in 282 adults with symptomatic oHCM randomly assigned to receive Myqorzo or placebo for 24 weeks. At the end of the study, participants receiving Myqorzo had an increase in exercise capacity measured by peak oxygen uptake compared to no change in exercise capacity among those receiving placebo. Also, 59 percent of participants receiving Myqorzo experienced an improvement in physical activity limitations (measured using the New York Heart Association Classification system) compared to 24 percent of individuals receiving placebo. Safety Information Myqorzo reduces contraction of the heart muscle, which can cause heart failure. Because of the risk for heart failure, patients treated with Myqorzo must be monitored with echocardiograms, an imaging test that shows how well the heart is working. Because of the heart failure risk and need for monitoring, Myqorzo is only available through a restricted program called the Myqorzo Risk Evaluation and Mitigation Strategy (REMS). Patients must also avoid certain prescription medicines that interfere with the metabolism (breakdown) of Myqorzo. See the prescribing information for additional information on risks associated with Myqorzo. Designations Myqorzo received Orphan Drug Designation and Breakthrough Therapy Designation for this indication.

FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older

FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older Action https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212320s019lbl.pdf?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration (FDA) approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency. Accrufer was initially approved in 2019 for adults with iron deficiency. Disease or Condition Iron deficiency is the most common cause of anemia and occurs if there is not enough iron in the blood. Without enough iron, the body cannot make sufficient hemoglobin, a protein inside red blood cells that carries oxygen throughout the body. Iron deficiency anemia can result in symptoms such as fatigue, pale skin, and dizziness. Causes can include blood loss from gastrointestinal conditions, menstruation, food malabsorption, and insufficient iron in the diet. Data Supporting Accrufer The efficacy of Accrufer to treat iron deficiency in pediatric patients ages 10-17 was assessed in the FORTIS trial (NCT05126901). The trial treated 24 patients with age-based dosing of Accrufer twice daily, and showed a clinically meaningful average increase in hemoglobin of 1.1 g/dL at Week 12. This, on average, would be the expected increase in hemoglobin with one blood transfusion. Safety Information Patients should not take Accrufer if they are allergic to Accrufer or any of its excipients, have hemochromatosis and other iron overload syndromes, or receive repeated blood transfusions. In addition, patients should avoid Accrufer if they are experiencing an inflammatory bowel disease flare and should be aware of the risks of iron overload. The most common side effects of Accrufer are flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting, and abdominal discomfort/distension.

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer: Updates and Insights Authors: Haley Ellis, MD; Steven Maron, MD, MSc

https://www.medscape.org/viewarticle/her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251223-OUS-HONC-her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3-cta

FDA Approves Novel Fibrinogen Concentrate for CFD Sharon Worcester December 23, 2025

https://www.medscape.com/viewarticle/fda-approves-novel-fibrinogen-concentrate-cfd-2025a100103u

Rural Cancer Survivors Are More Likely to Have Chronic Pain Edited by Katie Lennon December 23, 2025

https://www.medscape.com/viewarticle/rural-cancer-survivors-are-more-likely-have-chronic-pain-2025a100104r

Routine PSA Screening May Do More Harm Than Good Kenneth W. Lin, MD, MPH December 23, 2025

https://www.medscape.com/viewarticle/routine-psa-screening-may-do-more-harm-than-good-2025a1000zqw

ESMO: Pembrolizumab Neoadjuvant/Adjuvant Outperforms Adjuvant Alone in Stage III Melanoma Teresa Amaral, MD, PhD December 23, 2025

https://www.medscape.com/viewarticle/esmo-pembrolizumab-neoadjuvant-adjuvant-outperforms-adjuvant-2025a1000yk1

Novel CAR T Cells Show Promise for Resistant T-Cell ALL Edited by Gargi Mukherjee December 23, 2025

https://www.medscape.com/viewarticle/novel-car-t-cells-show-promise-resistant-t-cell-all-2025a100108d

FDA OKs Subcutaneous Mosunetuzumab for Follicular Lymphoma Sharon Worcester December 24, 2025

https://www.medscape.com/viewarticle/fda-oks-subcutaneous-mosunetuzumab-follicular-lymphoma-2025a1001093

Managing Progression on Frontline Immunotherapy: A Multidisciplinary Case Approach In Metastatic Melanoma Authors: Gino K. In, MD, MPH; Sunandana Chandra, MD, MS; Robert J. Lewandowski, MD; Ali Rastegarpour, MD

https://www.medscape.org/viewarticle/1002675?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251223-OUS-HONC-1002675-cta

martes, 23 de diciembre de 2025

What impact does melatonin have on sleep cycle? (Medscape AI)

Melatonin is an endogenous hormone that plays a central role in the timing and quality of sleep by acting on the body’s circadian system and facilitating sleep onset and maintenance. https://www.medscape.com/ai-search?query=What%20impact%20does%20melatonin%20have%20on%20sleep%20cycle%3F&ecd=wnl_tp10_daily_251217_MSCPEDIT_etid7962970&uac=148436CN&impID=7962970

Holiday Heart Syndrome: Which seasonal habits most often trigger atrial fibrillation (Medscape AI)

https://www.medscape.com/ai-search?query=Holiday%20Heart%20Syndrome:%20Which%20seasonal%20habits%20most%20often%20trigger%20atrial%20fibrillation&ecd=wnl_tp10_daily_251220_MSCPEDIT_etid7972120&uac=148436CN&impID=7972120 Holiday Heart Syndrome (HHS) is most commonly precipitated by behavioral changes during holiday periods that promote atrial fibrillation (AF). Key seasonal habits include:

CRC: How Ultraprocessed Foods and Sugary Drinks Impact Risk David A. Johnson, MD

https://www.medscape.com/viewarticle/crc-how-ultraprocessed-foods-and-sugary-drinks-impact-risk-2025a1000zq6?ecd=wnl_edit_tpal_etid7973201&uac=148436CN&impID=7973201

Colorectal cancer: experts discuss the clinical guidelines +... +... +... +...

Neoadjuvant Chemotherapy in Colon Cancer: Who Is the Ideal Candidate? https://decisionpoint.medscape.com/oncology/viewarticle/944624?src=0_nl_sm_0&uac=148436CN Chiara Cremolini, MD, PhD, University of Pisa Appendiceal Cancers: How Are They Different From Colon Cancer? https://decisionpoint.medscape.com/oncology/viewarticle/921574?src=0_nl_sm_0&uac=148436CN Katrina S. Pedersen, MS, MD, Washington University Molecular Profiling for Early-onset Colorectal Cancer (CRC) https://decisionpoint.medscape.com/oncology/viewarticle/930635?src=0_nl_sm_0&uac=148436CN John L. Marshall, MD, Georgetown University Treatment Options for Patients With MSI-H Locally Advanced Rectal Cancer https://decisionpoint.medscape.com/oncology/viewarticle/990258?src=0_nl_sm_0&uac=148436CN Katrina S. Pedersen, MS, MD, Washington University

Why are noncardiovascular deaths rising among patients with heart failure (Medscape AI) +...

https://www.medscape.com/ai-search?query=Why%20are%20noncardiovascular%20deaths%20rising%20among%20patients%20with%20heart%20failure&ecd=wnl_tp10_daily_251221_MSCPEDIT_etid7968996&uac=148436CN&impID=7968996 Patients with heart failure are living longer after acute ischemic events, but now face a growing burden of systemic comorbidities that drive non-cardiovascular mortality.

What are the patterns of drug-induced liver injury with GLP-1 agonists? (Medscape AI) +... +++++ ++ +

Position-wise mutation analysis and temporal changes in SARS CoV-2 Envelope (E) protein variants Anwesa Saha [1,†] , Diganta Mukherjee [1,†] , Aparna Mukhopadhyay* [1]

https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8011 SARS CoV-2 is a positive-sense, single-stranded RNA virus. The genome of the virus undergoes numerous mutations, making the development of universally effective drugs challenging. Among its structural proteins, the Envelope (E) protein acts as an ion transporter and virulence factor, making it a potential therapeutic target. Based on the literature available to date, we have identified several functionally important sites in the E protein. These include residues involved in lysosomal deacidification; those of the FYXY motif, involved in amyloid formation in the host; and the PDZ-binding DLLV motif. We focus our analysis on the significance of these residues while also searching for other interesting mutational patterns. In this study, we conducted a comprehensive mutational analysis of the SARS CoV-2 E protein utilizing bioinformatics, statistics, and structural modeling tools. Over 1.4 million sequences were retrieved from the NCBI virus database, filtered, clustered, and aligned chronologically. By employing a combination of web-based tools and in-house Python scripts, we analyzed per-residue Shannon entropy, mutation types, evolutionary pressure, and predicted structural impact (via ∆∆G). We observed a significant number of residues under diversifying selection. This suggests that new amino acids are being sampled at various positions in the protein, providing functional or structural benefits to the virus. A cyclical pattern of mutation and reversion was observed at position 9, stabilizing at a particular mutation. Similar trends appeared at position 11. These mutations may be functionally relevant, which need to be explored in future. However, the key regions have remained conserved over time. The evolution of cognitive abilities in marine animals: a hypothesis based on insights about cognition gene polymorphisms in Coelocanths and lungfish Zhizhou Zhang* [1], Shuaiyu Zhang [2], Yongdong Xu* [2] https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8001 Both coelacanths and lungfish have fossil evidence dating back 400 million years, placing them at a critical evolutionary juncture when marine animals transitioned to terrestrial environments. An intriguing question lies in the extent to which their cognitive abilities had evolved before they crawled onto land. While no fossil DNA exist for extinct coelacanths or lungfish, studies on their extant species offer clues. Notably, the biological traits of coelacanths and lungfish have been remarkably stable over the past 70 million years, suggesting that some genomic regions in their genomic sequences possess exceptional stability. This raises the possibility of inferring their cognition gene polymorphism patterns (CGPPs) and evolutionary positioning through genomic analyses of modern samples. By employing 471 whole-genome sequence samples, including archaic humans (Neanderthals, Denisovans and more), modern humans, other vertebrates (fish, amphibians, reptiles, birds, rodents, mammals) plus four coelacanth and three lungfish samples, together with 18 human cognition-related genes and their total of 223 SNVs (Single-Nucleotide Variations),comparative analyses revealed that the CGPPs of both coelacanths and lungfish are evolutionarily closer to those of archaic humans than those of most other animal groups. The CGPP appears to occupy an evolutionary inflection point, bridging diverse animal lineages to archaic hominoids. Our observational results suggest a hypothesis (to be validated in the future) that the genetic architecture underlying human cognitionseemsto have beenestablished during the evolutionary stage of fish, predating the emergence of tetrapods.

Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection Authors: Joyce A. O’Shaughnessy, MD; Aditya Bardia, MD, MPH, FASCO

https://www.medscape.org/viewarticle/1003008?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1003008-cta

FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219083s000lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition Action The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Disease or Condition Symptomatic oHCM is an inherited condition where patients have thickened heart muscle and reduced blood flow from the left side of the heart to the rest of the body, causing symptoms such as shortness of breath, fatigue, and potentially life-threatening cardiac events. Myqorzo Effectiveness The effectiveness and safety of Myqorzo were studied in 282 adults with symptomatic oHCM randomly assigned to receive Myqorzo or placebo for 24 weeks. At the end of the study, participants receiving Myqorzo had an increase in exercise capacity measured by peak oxygen uptake compared to no change in exercise capacity among those receiving placebo. Also, 59 percent of participants receiving Myqorzo experienced an improvement in physical activity limitations (measured using the New York Heart Association Classification system) compared to 24 percent of individuals receiving placebo. Safety Information Myqorzo reduces contraction of the heart muscle which can cause heart failure. Because of the risk for heart failure, patients treated with Myqorzo must be monitored with echocardiograms, an imaging test that shows how well the heart is working. Because of the heart failure risk and need for monitoring, Myqorzo is only available through a restricted program called the Myqorzo Risk Evaluation and Mitigation Strategy (REMS). Patients must also avoid certain prescription medicines that interfere with the metabolism (breakdown) of Myqorzo. See the prescribing information for additional information on risks associated with Myqorzo. Designations Myqorzo received Orphan Drug Designation and Breakthrough Therapy Designation for this indication.

Update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV

https://clinicalinfo.hiv.gov/en/news/update-guidelines-prevention-and-treatment-opportunistic-infections-children-and-exposed-hiv-2 Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new

San Antonio Breast Cancer Symposium (SABCS) 2025 Conference News

https://www.medscape.com/viewcollection/37937

NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC Edited by Joyani Das

https://www.medscape.com/viewarticle/nice-endorses-chemo-free-first-line-option-egfr-nsclc-2025a1000zyy

Moderately Hypofractionated Definitive Radiotherapy Linked to Favourable Outcomes in Inoperable Non-Extremity Sarcomas Edited by Vineeta Teotia

https://www.medscape.com/viewarticle/moderately-hypofractionated-definitive-radiotherapy-linked-2025a1000zkv

Novel Treatment Combo Ups Survival in Multiple Myeloma Sharon Worcester December 22, 2025

https://www.medscape.com/viewarticle/novel-treatment-combo-ups-survival-multiple-myeloma-2025a1000zz9

Childhood Cancer Survivors Face Long-Term Meningioma Risk Edited by Gargi Mukherjee December 22, 2025

https://www.medscape.com/viewarticle/childhood-cancer-survivors-face-long-term-meningioma-risk-2025a1001026

FDA Approves Novel Fibrinogen Concentrate for CFD Sharon Worcester December 23, 2025

https://www.medscape.com/viewarticle/fda-approves-novel-fibrinogen-concentrate-cfd-2025a100103u

Sexual Dysfunction in Cancer: More Common Than You Think Caroline Guignot

https://www.medscape.com/viewarticle/sexual-dysfunction-cancer-more-common-than-you-think-2025a100102s

Tumor-Like Masses, Abdominal Swelling, Pancreatic Involvement: Making Sense of IgG4-Related Disease, a Multiorgan Fibroinflammatory Condition Authors: Emanuel Della Torre, MD, PhD; J. Matthias Löhr, MD, PhD; John H. Stone, MD, MPH

https://www.medscape.org/viewarticle/1002730?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1002730-cta

FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212320s019lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older Action The U.S. Food and Drug Administration (FDA) approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency. Accrufer was initially approved in 2019 for adults with iron deficiency. Disease or Condition Iron deficiency is the most common cause of anemia and occurs if there is not enough iron in the blood. Without enough iron, the body cannot make sufficient hemoglobin, a protein inside red blood cells that carries oxygen throughout the body. Iron deficiency anemia can result in symptoms such as fatigue, pale skin, and dizziness. Causes can include blood loss from gastrointestinal conditions, menstruation, food malabsorption, and insufficient iron in the diet. Data Supporting Accrufer The efficacy of Accrufer to treat iron deficiency in pediatric patients ages 10-17 was assessed in the FORTIS trial (NCT05126901). The trial treated 24 patients with age-based dosing of Accrufer twice daily, and showed a clinically meaningful average increase in hemoglobin of 1.1 g/dL at Week 12. This, on average, would be the expected increase in hemoglobin with one blood transfusion. Safety Information Patients should not take Accrufer if they are allergic to Accrufer or any of its excipients, have hemochromatosis and other iron overload syndromes, or receive repeated blood transfusions. In addition, patients should avoid Accrufer if they are experiencing an inflammatory bowel disease flare and should be aware of the risks of iron overload. The most common side effects of Accrufer are flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting, and abdominal discomfort/distension.

Advanced Neuroendocrine Tumors: Integrating Emerging Targeted Therapies Into Patient Care Authors: Marianne Pavel, MD; Jaume Capdevila, MD, PhD; Rachel Riechelmann, MD, PhD; Simron Singh, MD, MPH, FRCPC

https://www.medscape.org/viewarticle/1002665?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251223-OUS-HONC-1002665-cta

lunes, 22 de diciembre de 2025

E-cigarette use is linked to higher heart attack risk, especially in former smokers

https://www.news-medical.net/news/20251214/E-cigarette-use-is-linked-to-higher-heart-attack-risk-especially-in-former-smokers.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_17_december_2025 A large meta-analysis suggests that vaping is not cardiovascularly neutral, with elevated heart attack risk concentrated among people who previously smoked, raising questions about e-cigarettes as harm-reduction tools.

Genes influence the gut microbiome beyond the individual

https://www.news-medical.net/news/20251219/Genes-influence-the-gut-microbiome-beyond-the-individual.aspx

Skin and internal organs sense cold through different molecular pathways

https://www.news-medical.net/news/20251219/Skin-and-internal-organs-sense-cold-through-different-molecular-pathways.aspx

Simple fruit granola intervention shows promising cardio-renal signals in CKD patients

https://www.news-medical.net/news/20251221/Simple-fruit-granola-intervention-shows-promising-cardio-renal-signals-in-CKD-patients.aspx A small Japanese study suggests that a low-salt, oat-based granola breakfast may improve blood pressure, lipid risk markers, and gut health indicators in people with moderate chronic kidney disease, while highlighting the need for larger controlled trials.

Study charts the escalating spread of resistant bacteria and fungi

https://www.news-medical.net/news/20251222/Study-charts-the-escalating-spread-of-resistant-bacteria-and-fungi.aspx

Cytokinetics heart drug wins FDA approval, the biotech’s first The clearance of Myqorzo ends one of the longest industry’s R&D droughts in the industry

https://www.statnews.com/2025/12/19/cytokinetics-heart-drug-myqorzo-fda-approval/ By Adam FeuersteinDec. 19, 2025 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Study revives debate about unpopular diet for cancer patients Neutropenic diet led to fewer infections in those with blood cancer By Angus ChenDec. 22, 2025 Cancer Reporter

https://www.statnews.com/2025/12/22/cancer-neutropenic-diet-lessened-risk-of-infection/ By Angus ChenDec. 22, 2025 Cancer Reporter

What Ozempic might tell us about the future of Alzheimer’s The GLP-1 might not treat Alzheimer’s, but it still offers lessons

https://www.statnews.com/2025/12/22/ozempic-alzheimers-iconic-drugs/ By Jason KarlawishDec. 22, 2025 Karlawish is a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, co-director of the Penn Memory Center, and executive producer of the “Age of Aging” podcast.

NIH study was a beacon for the topical steroid withdrawal community. Then, amid federal upheaval, the research stalled By Eric BoodmanDec. 22, 2025

NIH study was a beacon for the topical steroid withdrawal community. Then, amid federal upheaval, the research stalled Purchasing freeze and layoffs sidelined effort to help patients with a painful skin condition By Eric BoodmanDec. 22, 2025 https://www.statnews.com/2025/12/22/topical-steroid-withdrawal-study-derailed-american-science-shattered/

Advancing Precision Oncology: Recent Progress and Future Outlook Authors: Vivek Subbiah, MD; Elena Garralda, MD, MSc; Fernando Lopez-Rios, MD, PhD

https://www.medscape.org/viewarticle/advancing-precision-oncology-recent-progress-and-future-2025a1000a6b?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-advancing-precision-oncology-recent-progress-and-future-2025a1000a6b-cta

A 36-Year-Old Woman With Epigastric Pain, Dysphagia, Vomiting, and New Skin Changes Sarah El-Nakeep, MD December 11, 2025 (Case Challenge)

https://reference.medscape.com/viewarticle/36-year-old-woman-epigastric-pain-dysphagia-vomiting-and-new-2025a1000xx5?ecd=WNL_casechlg_251221_MSCPREF_etid7969200&uac=148436CN&impID=7969200 A 36-Year-Old Woman With Epigastric Pain, Dysphagia, Vomiting, and New Skin Changes A 36-year-old woman presents with a 1-month history of epigastric abdominal pain associated with several episodes of postprandial vomiting and a yearlong history of progressive dysphagia requiring liquids to facilitate swallowing. What's the diagnosis?

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-1002681-cta

Long COVID in Context: A Closer Look at Post-Viral Syndrome and Management Approaches Authors: Ziyad Al-Aly, MD; Bin Cao, MD

https://www.medscape.org/viewarticle/1002795?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-1002795-cta

Highlights From Milan 2025: Bispecific Antibodies in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Authors: Chan Cheah, MBBS, DMSc; Matthew Lunning, DO, FACP

https://www.medscape.org/viewarticle/1002726?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1002726-cta

FDA Approves Drug to Treat Chronic, Progressive Lung Disease

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220449s000lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Treat Chronic, Progressive Lung Disease Action The U.S. Food and Drug Administration (FDA) approved Jascayd (nerandomilast) tablets to treat adults with progressive pulmonary fibrosis (PPF). Jascayd was previously approved to treat idiopathic pulmonary fibrosis (IFP) in adults. Disease or Condition PPF is a chronic disease characterized by gradual, irreversible scarring of the lungs, which can lead to progressive breathing difficulties. PPF is an umbrella term that can describe progressive lung scarring in many interstitial lung diseases. Data Supporting Jascayd Jascayd’s efficacy for PPF was demonstrated in FIBRONEER-ILD (NCT05321082), a randomized, double-blind, placebo-controlled study that enrolled 1,178 adults with PPF. Participants were randomly assigned 1:1:1 to receive twice daily administration of Jascayd 9 mg, Jascayd 18 mg, or placebo for at least 52 weeks. Patients treated with either dose of Jascayd showed significantly slower rates of lung function decline compared to placebo, based on the primary endpoint of absolute change in forced vital capacity (FVC) — the maximum amount of air a person can forcefully exhale after taking the deepest possible breath — at 52 weeks. The adjusted, average decline in patients receiving 18 mg or 9 mg Jascayd was -72 mL and -85 mL, respectively, whereas the placebo group had a -151 mL decline. Additionally, patients receiving Jascayd had fewer events of either interstitial lung disease exacerbations, respiratory hospitalizations, or death over the course of the trial. The recommended dosages for Jascayd are 9 mg or 18 mg orally twice a day, approximately 12 hours apart. Safety Information The safety of Jascayd in patients with PPF was generally consistent with that observed in patients with IFP, a previously approved indication. Side effects include diarrhea, decreased weight, decreased appetite, and nausea. See the prescribing information for more safety information. Designation Jascayd received a Breakthrough Therapy Designation for the PPF indication.